| 產品編號 | bs-15523R-BF555 |
| 英文名稱 | Rabbit Anti-phospho-IFNGR1 (Tyr457)/BF555 Conjugated antibody |
| 中文名稱 | BF555標記的磷酸化干擾素gamma受體1蛋白抗體 |
| 別 名 | IFNGR1 (phospho Y457);p-IFNGR1 (phospho Y457); Antiviral Protein Type II; Antiviral protein, type 2; AVP type II; AVP, type 2; CD 119; CD119; CDw119; CD119 antigen; CDw119; FLJ45734; IFN gamma R alpha; IFN gamma R; IFN gamma R1; IFN-gamma receptor 1; IFN-gamma-R1; IFNG R1; IFNGR 1; IFNGR; IFNGR1; Immune interferon receptor 1; Immune interferon receptor for; INGR1_HUMAN; Interferon gamma receptor 1; Interferon gamma receptor alpha chain; Interferon gamma receptor alpha chain precursor. |
| 規格價格 | 100ul/2980元 購買 大包裝/詢價 |
| 說 明 書 | 100ul |
| 產品類型 | 磷酸化抗體 |
| 研究領域 | 微生物學 干細胞 細菌及病毒 細胞表面分子 淋巴細胞 t-淋巴細胞 b-淋巴細胞 細胞因子 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應 | Human, Mouse, |
| 產品應用 | ICC=1:50-200 IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 53kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthesised phosphopeptide derived from human IFNGR1 around the phosphorylation site of Tyr457 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 產品介紹 |
background: This gene (IFNGR1) encodes the ligand-binding chain(alpha) of the gamma interferon receptor. Human interferon-gamma receptor is a heterodimer of IFNGR1 and IFNGR2. A genetic variation in IFNGR1 is associated with susceptibility to Helicobacter pylori infection. In addition, defects in IFNGR1 are a cause of mendelian susceptibility to mycobacterial disease, also known as familial disseminated atypical mycobacterial infection. [provided by RefSeq]. Function: Receptor for interferon gamma. Two receptors bind one interferon gamma dimer. Subunit: Monomer. Subcellular Location: Membrane; Single-pass type I membrane protein. Post-translational modifications: Phosphorylated at Ser/Thr residues. DISEASE: Mendelian susceptibility to mycobacterial disease (MSMD) [MIM:209950]: This rare condition confers predisposition to illness caused by moderately virulent mycobacterial species, such as Bacillus Calmette-Guerin (BCG) vaccine and environmental non-tuberculous mycobacteria, and by the more virulent Mycobacterium tuberculosis. Other microorganisms rarely cause severe clinical disease in individuals with susceptibility to mycobacterial infections, with the exception of Salmonella which infects less than 50% of these individuals. The pathogenic mechanism underlying MSMD is the impairment of interferon-gamma mediated immunity, whose severity determines the clinical outcome. Some patients die of overwhelming mycobacterial disease with lepromatous-like lesions in early childhood, whereas others develop, later in life, disseminated but curable infections with tuberculoid granulomas. MSMD is a genetically heterogeneous disease with autosomal recessive, autosomal dominant or X-linked inheritance. Note=The disease is caused by mutations affecting the gene represented in this entry. Similarity: Belongs to the type II cytokine receptor family. Contains 2 fibronectin type-III domains. Contains 2 Ig-like C2-type (immunoglobulin-like) domains. Database links: Entrez Gene: 3459 Human Entrez Gene: 15979 Mouse Omim: 107470 Human SwissProt: P15260 Human SwissProt: P15261 Mouse Unigene: 520414 Human Unigene: 549 Mouse Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| 1、抗體溶解方法 | |
| 2、抗體修復方式 | |
| 3、常用試劑的配制 | |
| 4、免疫組化操作步驟 | |
| 5、免疫組化問題解答 | |
| 6、Western Blotting 操作步驟 | |
| 7、Western Blotting 問題解答 | |
| 8、關于肽鏈的設計 | |
| 9、多肽的溶解與保存 | |
| 10、酶標抗體效價測定程序 | |
